EIDD-2801

A prodrug form of EIDD-1931

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥737.00

590.00

- +
10mg

￥1075.00

860.00

- +
50mg

￥3212.00

2570.00

- +
100mg

￥4900.00

3920.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. EIDD-2801 has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-2801 has the potential for COVID-19, and seasonal and pandemic influenza treatment.

Reference：
[1]. Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883.
[2]. Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866.

Protocol

EIDD-2801 (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease^[1].
EIDD-2801 (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever^[2].

Animal Model:	C57BL/6 mice (intranasal infection with SARS-CoV)^[1]
Dosage:	50, 150, 500 mg/kg
Administration:	Oral; every 12 hours for 3 days
Result:	Body weight loss is significantly diminished or prevented.

Animal Model:	Ca/09-infected female ferrets^[1]
Dosage:	7 mg/kg
Administration:	Oral; twice daily for 3.5 days
Result:	Shed virus load and duration of fever were significantly reduced.